Gubra to receive double-digit million payment after obesity drug enters Phase 2 trial

Danish biotechnology company Gubra has earned a double-digit million payment following the initiation of a Phase 2 clinical trial by its partner…

Co-developed by the two companies, this drug is considered a novel approach in obesity treatment.